3rd ESTRO Forum 2015 S497 appeared sufficient for BAM. The slightly inferior results on target coverage for MSM are likely due to the variations of the femoral head positions influencing proton range and dose distribution.
Conclusions:
Tumour shrinkage had a statistically significant impact on the delivered doses to the spinal cord and the mandible. The dose increase found is modest in both organs in spite of considerable tumour shrinkage. Standard plans and dose-painted plans created using the CONTRAST protocol are equally robust with regard to the spinal cord and the increase in dose is probably clinically irrelevant. Standard plans appear more robust than CONTRAST plans with regard to the mandible, due to high dose boosting of regions close to the OAR (see figure 1 ). For cases where large tumours are in proximity of an important OAR and a large tumour shrinkage is observed, an adaptive strategy may be necessary.
PO-0948
Adaptive proton therapy using CBCT to calculate daily dose and range variations B. Winey 1 , Y.K. Park 1 , J. Phillips 1 , G.C. Sharp 1 1 Massachusetts General Hospital, Radiation Oncology, Boston MA, USA Purpose/Objective: To use cone beam computed tomography (CBCT) images for reliable and robust proton dose and range calculations. Scatter induced reconstruction errors are the dominant artifacts affecting CBCT HU accuracy. In order to generate a CBCT image for reliable dose and range calculations, scatter effects must be removed. Materials and Methods: Two common scatter correction methods were tested: uniform scatter model and a priori CT based scatter generation. Images were acquired for a electron density calibration phantom, multiple anthropomorphic phantoms, and patients selected from multiple treatment locations including cranial, prostate, and thoracic. For the phantom studies the diagnostic CT was considered to be the gold standard for dose and range calculations. For the patient studies, all daily comparisons are to the first daily CBCT and the planning CT. Water equivalent path lengths and doses to the PTVs using a 3D gamma analysis were analyzed. Additional phantom experiments were conducted to evaluate mild deformations simulating weight gain/loss and rectal filling/draining. Results: For the phantom tests, uncorrected CBCT reconstructions had the largest HU value differences compared to the reference CT while the a priori scatter corrected CBCT reconstruction had the most accurate HU values. Regarding WEPL, the uncorrected CBCT had average of errors of 5-13 mm depending upon the phantom size and herterogeneities. A uniform scatter corrected CBCT had average range error of 3-22 mm and the a priori scatter corrected CBCT had average range errors of 1-3 mm (See Table) . All WEPL errors were calculated using the refence CT of the phantoms. Doses were calculated in the same phantoms using targets simulating realistic clinical scenarios and beam combinations routinely used in the clinic. Gamma pass rates for 2%/2mm and 3%/3mm were always highest for the a priori scatter corrected CBCT at 96% and 99%, respectively. For uniform corrected CBCT dose calculations, the gamma pass rates were 78% (2%/2mm) and 86% (3%/3mm) with the worst cases being in the thorax due to an overestimation of the uniform scatter model with less attenuation and scatter in the lung. Patient doses were calculated with similar gamma pass rates but gamma rates varied more due to the realistic presence of patient daily variations of shape, target position and deformation of internal anatomy (see Figure for Prostate Example).
Conclusions:
Daily CBCT can be used for daily proton dose and range calculations for adaptive proton therapy when using an a priori scatter correction method. WEPL errors have been reduced from 13 mm to 3 mm and dose calculations can be performed with gamma 2%/2mm errors of less than 4%. Deformations due to weight gain/loss and target motion can be assessed with the proposed reconstruction methods. Further refinements in the CBCT reconstruction accounting for beam hardening and HU calibration specificity can reduce the range error below 3 mm. Purpose/Objective: A concern with the use of VMAT in hypofractionated lung treatments is whether tumour motion will lead to significant discrepancies between calculated and planned dose distributions. Our study aimed at: a) Evaluating whether planning on the average CT scan (AVG CT) allows for a good representation of the dose distribution delivered to the moving target when 'interplay' is not considered; b) Quantifying the interplay effect between tumour motion and dose delivery using a moving phantom and GafChromic EBT3 films.
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PO-0949 Advantages and shortcomings of planning hypofractionated lung treatments with VMAT on the average CT
Materials and Methods:
Patients For ten patients who received lung treatment (54 Gy in 3 fractions), VMAT plans generated with Monaco TPS on the AVG CT were recalculated on each phase of the 4DCT and the resulting plans were compared. A Philips BigBore CT scanner was used to acquire and reconstruct images (retrospective method based on phase detection). All patients had an ITV defined using the maximum intensity projection (MIP). A PTV was created as a 5 mm isotropic expansion of the ITV. Phantom A motor driven moving phantom was customized with an addon device consisting of a circular 3 cm diameter tissue equivalent sphere in polystyrene. The phantom moves in the cranio-caudal direction (2 cm peak-to-peak), with a frequency of 15 cycles/min and with an 'inspiration' phase shorter than the 'expiration' phase. EBT3 films can be inserted in the sphere simulating the target. Plans were generated on the AVG CT in two different ways: 1) with no density override and 2) setting the ITV density to the mean GTV density and the PTV-ITV shell to an intermediate density between lung and GTV. The density override was performed with the further aim of reducing the dose distribution modulation that is induced by the difference in density between ITV and PTV-ITV, but which is neither intentional nor desired. In order to single out the interplay effect, plans were also generated optimizing and prescribing to the ITV only (both with and without density override). Average treatment time was 10 min (150 cycles per treatment).
Results: Patients
In Table the results of the patient plan are reported, showing moderate variations between the AVG CT plan and the plans recalculated on each phase of the 4DCT. None of the parameters shows any statistically significant correlation between the variation and the extent of tumour displacement.
